SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports suggesting that GameStop may be preparing a takeover offer for the e-commerce giant, sparking intense debate among investors regarding the feasibility and logic of such a merger. The community is actively discussing the massive valuation gap, potential financing obstacles, and whether this narrative is a genuine strategic pivot or a speculative-driven market event.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

The community is rallying behind the token's identity as the original AI dog associated with Grok, highlighting its unique lore and recent exchange listing as key catalysts. Enthusiasts are actively discussing the ticker's long-term potential in the AI-meme sector, often emphasizing the project's deflationary mechanics and organic, community-driven growth.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as a segment of the community remains highly bullish, pointing toward active token burns, anticipated ecosystem project launches, and potential long-term price recovery. While some investors advocate for holding in hopes of a major supply shock, others are actively debating the token's future utility and the historical context of its market performance.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as speculators aggressively debate the potential for massive percentage gains while others warn of volatility and compare the asset to other community-driven meme projects. The community remains hyper-focused on monitoring volume, navigating whale activity, and looking for signs of upward momentum.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is trending following positive Phase 3 clinical data for its cancer treatment Ziihera, which has sparked significant discussion regarding the drug's potential to become a new standard of care in oncology. Community sentiment remains focused on the company's long-term pipeline potential and its ability to secure M&A interest from larger industry players.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is experiencing significant community momentum and social buzz, with investors actively discussing potential exchange listings and the goal of shedding multiple zeros from its price. While some market participants raise concerns about its large supply and historical performance, the community remains focused on potential breakout growth driven by upcoming network utility and broader altcoin market recovery.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the FEI-NY and FEI-Zyfer business segments. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is seeing significant investor attention driven by a record-high funded backlog and a series of strategic contracts in satellite and quantum sensing technologies. The community is actively discussing the stock's potential for long-term growth as it pivots to next-generation defense applications while maintaining a debt-free balance sheet.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is gaining traction as community members highlight its role as a core DEX on Solana, driving excitement around the project's ecosystem integration and active trading environment. Discussion is further fueled by the ongoing presence of community-led memecoin initiatives like $UPDOG, which leverage Jupiter's strict list to maintain visibility and engagement.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is currently generating intense community debate as traders split between bullish optimism over potential real-world asset integration and bearish warnings from skeptics who view recent price action as a classic pump-and-dump trap. The conversation remains highly polarized, with active discussion focusing on the token's long-term utility versus its history of volatility and increasing circulating supply.

Daddy Darth Vader

Daddy Darth Vader is trending as investors debate the project's future amidst intense community rivalries, with many participants speculating on potential market activity and comparing it to other memecoins. Holders are actively discussing strategies to push the token forward, emphasizing community-driven growth and upcoming milestones to sustain momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>SENTI-202, the immune cell therapy cancer treatment, received a Regenerative Medicine Advanced Therapy (RMAT) designation that would make it eligible for quicker reviews.</li><li>This is the second FDA designation for the treatment this year.&nbsp;</li><li>On Stocktwits, retail sentiment for the stock rose to ‘extremely bullish’ territory while message volume jumped to ‘extremely high’ levels at the time of writing. &nbsp;</li></ul>Shares of Senti Biosciences, Inc. (SNTI) surged over 20% on Tuesday’s premarket trading after the company announced positive news around its cancer treatment.&nbsp;The clinical-stage biotech company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-updated-senti-202-clinical-data-ongoing">announced</a> in a press release that the U.S. Food and Drug Administration (FDA) gave SENTI-202, an immune cell therapy cancer treatment, a Regenerative Medicine Advanced Therapy (RMAT) designation.&nbsp;<h2 class="st-heading-2">What Does This Mean?</h2>The RMAT designation from the FDA for the company’s cancer treatment indicates an expedited development and review, providing benefits similar to the FDA’s Breakthrough Therapy and the Fast Track programs such as higher interactions with the Agency through the development process as well as eligibility for quicker and even priority reviews.“This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” said Timothy Lu, Co-Founder and CEO of Senti Biosciences, in the press release. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”Data from its ongoing trial showed a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose, the company revealed. Earlier this year, the U.S. FDA granted the treatment Orphan Drug Designation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/SNTI">SNTI</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1284/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_7_13_22_PM_png_c037e194c0.webp" alt="On Stocktwits, retail sentiment around&nbsp;SNTI jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels." width="1284" height="149"></figure>One user on the platform predicted that STNI’s share price could go up to $5. The stock was trading around $2.85 at the time of writing.&nbsp;<stembedurl>https://stocktwits.com/Stratsys/message/638587949</stembedurl>Shares of SNTI have fallen over 37% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment 

Equity

Shares of Senti Biosciences Inc. skyrocketed over 400% on Monday afternoon, making it the top gainer across U.S. stock exchanges and the top trending ticker on Stocktwits.&nbsp;The surge was fueled by the biotech company’s announcement of an oversubscribed private placement and promising early clinical data for its experimental blood cancer treatment.&nbsp;The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.Senti disclosed that it had entered into a securities purchase agreement with existing and new accredited investors to raise approximately $37.6 million through the sale of Series A&nbsp;convertible preferred stock in a private investment in public equity (PIPE) financing.&nbsp;The deal includes warrants allowing investors to purchase up to an additional 25,069,500 shares of the company’s common stock, contingent on shareholder approval.&nbsp;Additionally, an option was granted to a specific investor to buy 4,444 more shares of preferred stock and accompanying warrants, potentially generating $10 million more in gross proceeds by Dec. 27.The PIPE financing, led by Celadon Partners and supported by institutional players like New Enterprise Associates, Leaps by Bayer, and Nantahala Capital, is expected to close by Thursday.&nbsp;Senti plans to use the proceeds to advance its SENTI-202 program, scale manufacturing capabilities, support ongoing R&amp;D efforts, and for general corporate purposes.Positive clinical data from the Phase 1 trial of SENTI-202 also contributed to the stock’s meteoric rise.&nbsp;The trial focused on treating acute myeloid leukemia and other relapsed or refractory hematologic cancers using Senti’s proprietary gene circuit technology.&nbsp;Initial results revealed that two of three treated patients achieved complete remission, confirmed by bone marrow biopsy, with both patients remaining in remission for three and four months, respectively.&nbsp;The treatment was reported to have a generally well-tolerated safety profile at the administered dose, with further trial updates expected next year as dose escalation continues.<figure class="image"><a href="https://stocktwits.com/symbol/SNTI"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SNTI_sentiment_meter_and_message_volume_on_Dec_2_42660f4d88.png" alt="SNTI sentiment meter and message volume on Dec 2.png" width="1314" height="320"></a><figcaption>SNTI sentiment meter and message volume on Dec 2 as of 1:00 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for SNTI turned ‘extremely bullish’ amid soaring message volume.<stembedurl>https://stocktwits.com/DJTAZ/message/594734529</stembedurl><stembedurl>https://stocktwits.com/Pianomemo/message/594734011</stembedurl>Year-to-date, Senti Biosciences shares have gained over 70%, with Monday’s explosive rally marking a pivotal moment for the company’s visibility in the biotech sector.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Senti's deal includes warrants allowing investors to purchase up to an additional 25,069,500 shares of the company’s common stock

Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed

The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.

This account has been verified as an official SNTI representative.

Verified Account

Senti Biosciences

Operates as a holding company whose subsidiary develops cell and gene therapies for cancer diseases

SNTI
Senti Biosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SNTI News

SNTISenti Biosciences Inc.